Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1891-1900 of 2869 for cancer

Edit search filters
  1. A Open Label Study Of The Efficacy And Safety Of PD0332991 A Selective Inhibitor Of The Cyclin Dependent Kinases 4 And 6 In Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency And Low P16 Expression

    Rochester, MN

  2. A Study Of MPDL3280A (Anti-PD-L1 Antibody) Combined With Carboplatin And Paclitaxel , And With Or Without Bevacizumab, For Patients Who Have Stage IV Non-Squamous Non-Small Cell Lung Cancer

    Jacksonville, FL

  3. DESTINY-Endometrial01: A Phase III Study Of Trastuzumab Deruxtecan Plus Rilvegostomig Or Pembrolizumab As First-Line Treatment Of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    Rochester, MN

  4. A Study Evaluating Safety And Efficacy Of The Addition Of ABT-888 Plus Carboplatin Versus The Addition Of Carboplatin To Standard Chemotherapy Versus Standard Chemotherapy In Subjects With Early Stage Triple Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. Study Of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily And In Combination With Dabrafenib Twice Daily And Trametinib Once Daily In Combination Therapy In Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  6. Outcomes After Secondary Cytoreductive Surgery With Or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed By Systemic Combination Chemotherapy For Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

    Rochester, MN

  7. A Study Assessing The Effectiveness And Safety Of Alpelisib Plus Fulvestrant In Men And Postmenopausal Women Who Have Advanced Breast Cancer Which Progressed On Or After Aromatase Inhibitor Treatment

    Scottsdale/Phoenix, AZ

  8. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Jacksonville, FL, Rochester, MN

  9. Olaparib And Onalespib In Treating Patients With Solid Tumors That Are Metastatic Or Cannot Be Removed By Surgery Or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, Or Triple-Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Study To Assess Adverse Events And Change In Disease Activity In Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer In Combination With IV Fluorouracil, Folinic Acid, And Bevacizumab

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer